ArticleFrontiers in cellular and infection microbiology2026
A novel multiplex approach for the comprehensive analysis of the Epstein-Barr virus-specific humoral immune response.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Epstein-Barr virus (EBV) is an oncogenic herpesvirus that establishes lifelong infections in more than 90% of the human population. EBV infection is typically diagnosed using serological assays, which also distinguish between acute and persistent infection. However, current diagnostic approaches rely on a limited set of viral proteins and may therefore fail to detect disease-specific antibody signatures associated with EBV-related cancers or autoimmune diseases. Comprehensive profiling of humoral responses against the complete EBV proteome could improve the sensitivity and specificity of serological diagnostics. Methods: We developed a serological multiplex assay covering all EBV proteins expressed in human cells, enabling measurement of virus-specific IgM, IgG, and IgA responses. The assay was evaluated using sera from healthy EBV carriers and EBV-negative controls. Near-infrared detection was employed to support quantitative analysis across a broad dynamic range. Performance was benchmarked against commercially available serological assays. Results: The multiplex assay demonstrated a broad dynamic range with linear quantification across several orders of magnitude. Comparative evaluation showed that the assay achieved sensitivity and specificity comparable to established commercial tests while enabling comprehensive antibody profiling against the full EBV proteome. Conclusion: This multiplex serological platform provides a robust approach for comprehensive characterization of EBV-specific humoral immune responses. By extending antibody profiling beyond the limited antigen panels used in routine diagnostics, the assay may facilitate the identification of novel biomarkers for EBV-associated cancers and autoimmune diseases. Future applications could contribute to improved diagnostic accuracy and support the development of targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.